Navigation Links
Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
Date:2/23/2009

ADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.

Important Safety Information

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
2. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
3. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
5. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
6. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
7. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
8. Inexpensive and Illegal Buttock - Boosting Injections Not Pretty
9. Radiofrequency treatment better than ethanol injection for small liver tumors
10. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
11. Cosmetic Injections A Worthwhile Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... The healthcare analytics market is categorized ... Factors such as the rising pressure to curb healthcare costs, big data in ... capital investments are driving market growth. Check 149 data tables & 57 figures ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... ... ... Orthopedic surgeons at Lourdes Medical Center of Burlington County are the first in ... to treat a common source of shoulder pain and disability. , The minimally ... could allow for faster healing and a decreased chance of future tendon tearing. ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... ... July 29, 2015 , ... It is unique for a health center to ... of care. One that is very hands on and resident oriented, and one to ... “She’s bringing great passion and energy, as well as a strong commitment to helping ...
Breaking Medicine News(10 mins):Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3
... 10, 2008 IPC,The Hospitalist Company, Inc. (Nasdaq: ... the delivery of hospitalist medicine services,announced today that it ... 31, 2008 on Wednesday, May 14, 2008, after the ... results will begin at 5:00 p.m. ET,(2:00 p.m. PT) ...
... available for comment, PHILADELPHIA, April 10 The ... letter on,Thursday, calling on the major Democratic candidates campaigning ... healthcare access and,lower costs in SB 1137, HB 2098 ... 10, 2008, Dear Senator Clinton and Senator Obama:, ...
... Why are you so disappointed?, CHICAGO, April 10 ... It has to do with changing expectations., Businesses ... an attitude,that says, "We need a web presence. Now!" We ... the web!, This realization is usually followed by weeks ...
... Meets Number One Consumer Request, PLANO, Texas, April ... the launch of Pinch of Salt, a,low-sodium version of ... Tostitos tortilla chips, Fritos corn chips and Ruffles potato ... to begin with,-- for instance Lay,s Classic potato chips ...
... BENSALEM, Pa., April 9 Law Offices of ... against Merck & Co., Inc.,("Merck" or the "Company")(NYSE: ... and Security Plan (the "Plan") imprudently invested in,Merck ... fiduciary,duties to the Plan,s participants in violation of ...
... ANGELES, April 9 The Los Angeles ... children hospitalized for,cancer and other serious illnesses, ... a half block from its original Fountain ... low cost, often free, lodging to,75-families per ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2008 Financial Results 2Health News:Open Letter to Presidential Candidates on State Health Care Reform 2Health News:So ... You Went and Got a Pretty Web Site. 2Health News:Frito-Lay Launches Low Sodium Versions of its Top Selling Snack Chips 2Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 2Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 3
(Date:7/29/2015)... July 29, 2015 At the 2015 ... will present findings that a first-of-its-kind smartphone test ... accuracy, which could reduce the prevalence of this ... easier and cheaper. Most people with ... infection often causes no symptoms, but if left ...
(Date:7/29/2015)... DUBLIN , July 27, 2015 ... the addition of the "Pharmaceutical Packaging Market by ... by Region(North America, Europe, Asia-Pacific, RoW) - Forecasts to ... global pharmaceutical packaging market demand, by value is estimated ... The pharmaceutical packaging market is anticipated to show a ...
(Date:7/29/2015)... RATON, Fla. , July 29, 2015 /PRNewswire/ ... launch of Azelastine HCl Nasal Solution, 0.1%. The U.S. ... Abbreviated New Drug Application (ANDA), which is AB ... Pharmaceuticals. Azelastine hydrochloride nasal solution (nasal spray) is ... June 2015 IMS Health sales data.  Azelastine HCl ...
Breaking Medicine Technology:First Smartphone DNA Test for Chlamydia to Be Presented at 2015 AACC Annual Meeting 2First Smartphone DNA Test for Chlamydia to Be Presented at 2015 AACC Annual Meeting 3Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 3
... Reviews enable all those involved with healthcare ... the very latest evidence in their field ... harder each year as the volume of ... by delivering the best single source available ...
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
The perfect quick consult for the busy cardiologist, The Ultimate Echo Guide puts the most clinically essential information in an easy access format....
Medicine Products: